EA200500169A1 - Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение - Google Patents

Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение

Info

Publication number
EA200500169A1
EA200500169A1 EA200500169A EA200500169A EA200500169A1 EA 200500169 A1 EA200500169 A1 EA 200500169A1 EA 200500169 A EA200500169 A EA 200500169A EA 200500169 A EA200500169 A EA 200500169A EA 200500169 A1 EA200500169 A1 EA 200500169A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diphenylprop
application
receiving
substituted derivatives
derivatives
Prior art date
Application number
EA200500169A
Other languages
English (en)
Other versions
EA011090B1 (ru
Inventor
Жамила Нажиб
Карин Комон-Бертран
Original Assignee
Женфит
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Женфит filed Critical Женфит
Publication of EA200500169A1 publication Critical patent/EA200500169A1/ru
Publication of EA011090B1 publication Critical patent/EA011090B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids

Abstract

Настоящее изобретение относится к новым замещенным производным 1,3-дифенилпроп-2-ен-1-она, к содержащим их фармацевтическим композициям, их применению в терапии, в частности для лечения ишемии мозга. Оно также относится к способу получения этих производных.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500169A 2002-07-08 2003-07-08 Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение EA011090B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0208571A FR2841900B1 (fr) 2002-07-08 2002-07-08 Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
PCT/FR2003/002127 WO2004005233A1 (fr) 2002-07-08 2003-07-08 Derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations

Publications (2)

Publication Number Publication Date
EA200500169A1 true EA200500169A1 (ru) 2005-06-30
EA011090B1 EA011090B1 (ru) 2008-12-30

Family

ID=29725283

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500169A EA011090B1 (ru) 2002-07-08 2003-07-08 Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение

Country Status (24)

Country Link
US (3) US7943661B2 (ru)
EP (1) EP1525177B1 (ru)
JP (1) JP4575771B2 (ru)
KR (1) KR100974577B1 (ru)
CN (1) CN100548960C (ru)
AT (1) ATE365703T1 (ru)
AU (1) AU2003264698B2 (ru)
BR (1) BRPI0312398B8 (ru)
CA (1) CA2490986C (ru)
CY (1) CY1108085T1 (ru)
DE (1) DE60314633T2 (ru)
DK (1) DK1525177T3 (ru)
EA (1) EA011090B1 (ru)
ES (1) ES2287528T3 (ru)
FR (1) FR2841900B1 (ru)
IL (2) IL165696A0 (ru)
MX (1) MXPA05000427A (ru)
NO (1) NO329700B1 (ru)
NZ (1) NZ538051A (ru)
PL (1) PL207362B1 (ru)
PT (1) PT1525177E (ru)
SI (1) SI1525177T1 (ru)
WO (1) WO2004005233A1 (ru)
ZA (1) ZA200501082B (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
JP2007517841A (ja) * 2004-01-08 2007-07-05 ジェンフィット １，３−ジフェニルプロプ−２−エン−１−オン誘導体化合物、その調製方法およびその使用
FR2902789A1 (fr) 2006-06-21 2007-12-28 Genfit Sa Derives de 1,3-diphenylpropane substitues, preparations et utilisations
US20100285126A1 (en) * 2007-08-02 2010-11-11 Rahul Dabre Pharmaceutical compositions of fenofibrate
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
CA2781451C (en) * 2009-11-26 2019-04-16 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2011080276A1 (en) 2009-12-29 2011-07-07 Genfit Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative
DK2571843T3 (da) 2010-05-17 2018-01-29 Genfit Forbedret fremstilling af chalcon-derivater
TWI415600B (zh) * 2011-08-10 2013-11-21 Univ Kaohsiung Medical 用於治療動脈粥狀硬化的組合物及其製備方法
KR102023667B1 (ko) 2011-12-28 2019-09-23 장피트 1,3-디페닐프로판 유도체, 그 제조 및 용도
CN102697757B (zh) * 2012-05-18 2014-06-04 广州军区广州总医院 对羟基苄叉丙酮在制备预防和/或治疗脑病药物中的应用
ES2702038T3 (es) * 2013-01-18 2019-02-27 Genfit Métodos de tratamiento de fibrosis y cánceres
WO2017143038A1 (en) * 2016-02-16 2017-08-24 Concert Pharmaceuticals, Inc. Deuterated gft-505
CA3018132C (en) 2016-03-31 2024-02-13 Genfit Use of elafibranor in the treatment of a cholestatic disease
FR3056908B1 (fr) 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
FR3056909B1 (fr) 2016-09-30 2019-04-19 Nashpharm Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree
CA3047098A1 (en) * 2016-12-16 2018-06-21 Jia Zhou Inhibitors of bromodomain-containing protein 4 (brd4)
JP2020505355A (ja) * 2017-01-22 2020-02-20 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド Ｇｆｔ−５０５の結晶形及びその製造方法並びに用途
MX2019009908A (es) 2017-02-21 2019-10-14 Genfit Combinacion de un agonista de ppar con un agonista de fxr.
EP3585384A1 (en) 2017-02-24 2020-01-01 Genfit Pharmaceutical compositions for combination therapy
AU2018254743B2 (en) 2017-04-18 2024-04-11 Genfit Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor
CN108658908B (zh) * 2017-07-31 2019-05-10 广州必贝特医药技术有限公司 1，3-二取代烯酮类化合物及其应用
BR112020002261A2 (pt) 2017-08-04 2020-07-28 Advitech Advisory And Technologies Sa processo para a preparação de elafibranor, composto e uso de pelo menos um composto
JP2020533339A (ja) 2017-09-13 2020-11-19 ノバルティス アーゲー Ｆｘｒアゴニストを含む組合せ
EP3710425A1 (en) 2017-11-16 2020-09-23 Teva Pharmaceuticals International GmbH Solid state forms of elafibranor
WO2019105234A1 (zh) 2017-11-30 2019-06-06 四川科伦博泰生物医药股份有限公司 芳香族化合物及其药物组合物和用途
EP3514541A1 (de) * 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
WO2019186410A1 (en) * 2018-03-27 2019-10-03 Lupin Limited Solid forms of elafibranor and processes thereof
US20210309608A1 (en) 2018-08-03 2021-10-07 Genfit Elafibranor salts
WO2020039297A1 (en) * 2018-08-24 2020-02-27 Mankind Pharma Ltd. Novel compounds and their use in preparation of elafibranor and pharmaceutical acceptable salts thereof
WO2020115628A1 (en) * 2018-12-03 2020-06-11 Mankind Pharma Ltd. Solid forms of elafibranor and process of preparation thereof
CN110156648A (zh) * 2019-05-30 2019-08-23 河北科技大学 一种Elafibranor中间体的制备方法
WO2021083912A1 (en) 2019-10-28 2021-05-06 Genfit Combination therapy having antioxydant properties
CN112824380A (zh) * 2019-11-21 2021-05-21 杭州百诚医药科技股份有限公司 α-氟代查耳酮类衍生物及其应用
CN111138264B (zh) * 2019-11-29 2023-08-04 温州医科大学 一种丁香醛衍生物及其在制备抗妇科肿瘤药物中的应用
CN113121394B (zh) * 2019-12-30 2022-11-08 中国药科大学 一种苯氧乙酸类衍生物的制备方法
WO2021160520A1 (en) 2020-02-10 2021-08-19 Genfit Polymorphs of elafibranor
TW202207911A (zh) 2020-05-18 2022-03-01 法商Ｇｅｎｆｉｔ公司 治療原發性硬化性膽管炎之方法
BR112023003317A2 (pt) 2020-08-26 2023-03-21 Genfit Composições e métodos para o tratamento da colangite biliar primária
CN113230240B (zh) * 2021-03-22 2022-12-27 广州医科大学 1,3-二苯基丙-2-烯-1-酮衍生物及其应用
CN114853686B (zh) 2021-08-23 2023-06-20 中国药科大学 三氮唑酮类化合物及其医药用途
CN115894379A (zh) 2022-01-20 2023-04-04 中国药科大学 海因类化合物及其医药用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558612A (en) 1968-05-22 1971-01-26 Dow Chemical Co Substituted phenoxyacetic acids
CH593224A5 (ru) * 1973-10-30 1977-11-30 Taisho Pharmaceutical Co Ltd
US3994955A (en) * 1975-01-20 1976-11-30 G. D. Searle & Co. Substituted phenoxydialkylacetic acids and esters
JPS5278856A (en) 1975-12-26 1977-07-02 Taisho Pharmaceut Co Ltd Preparation of chalcone ethers
US4190671A (en) * 1977-03-17 1980-02-26 Biorex Laboratories Limited Chalcone derivatives
JPS5419947A (en) 1977-07-16 1979-02-15 Taisho Pharmaceut Co Ltd Chalcone derivatives
GB8426424D0 (en) * 1984-10-19 1984-11-28 Biorex Laboratories Ltd Chalcone derivatives
JPS6310720A (ja) 1986-07-01 1988-01-18 Nippon Kayaku Co Ltd ５−リポキシゲナ−ゼ阻害剤および抗アレルギ−剤
JPH023670A (ja) * 1988-06-22 1990-01-09 Nippon Oil & Fats Co Ltd アルキルチオカルコン誘導体
CA2003856C (en) 1988-11-25 1996-01-30 Toshio Satoh Therapeutic agent for renal disorders
JPH0442229A (ja) * 1990-06-08 1992-02-12 Fujitsu Ltd レジスト材料およびパターンの形成方法
JPH05255655A (ja) 1992-03-12 1993-10-05 Kanebo Ltd 紫外線吸収剤
JPH06122623A (ja) 1992-10-09 1994-05-06 Minofuaagen Seiyaku Honpo:Goushi 抗腫瘍剤
US5276058A (en) * 1993-06-09 1994-01-04 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
DE4327365A1 (de) 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
US5523302A (en) 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
EP0947511A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
WO2000023073A1 (en) 1998-10-20 2000-04-27 Korea Institute Of Science And Technology Bioflavonoids as plasma high density lipoprotein level increasing agent
KR100711537B1 (ko) * 2000-01-27 2007-04-27 다카라 바이오 가부시키가이샤 치료제
KR20030031500A (ko) * 2000-06-20 2003-04-21 아테로제닉스, 인코포레이티드 1,3-비스-(치환된-페닐)-2-프로펜-1-온 및 ｖｃａｍ-1매개된 질환을 치료하기 위한 그의 용도
EP1254759B1 (de) 2001-05-03 2009-03-18 Leister Process Technologies Düse zum Schweissen von Kunststoffbahnen oder -folien
FR2841784B1 (fr) * 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
JP2007517841A (ja) * 2004-01-08 2007-07-05 ジェンフィット １，３−ジフェニルプロプ−２−エン−１−オン誘導体化合物、その調製方法およびその使用

Also Published As

Publication number Publication date
BRPI0312398B8 (pt) 2021-05-25
SI1525177T1 (sl) 2007-10-31
ZA200501082B (en) 2007-01-31
FR2841900A1 (fr) 2004-01-09
US20110190515A1 (en) 2011-08-04
DE60314633D1 (de) 2007-08-09
NO20045301L (no) 2005-02-04
AU2003264698A1 (en) 2004-01-23
BR0312398A (pt) 2005-04-12
DE60314633T2 (de) 2008-02-28
BRPI0312398B1 (pt) 2016-11-08
US7943661B2 (en) 2011-05-17
PL372809A1 (en) 2005-08-08
EP1525177A1 (fr) 2005-04-27
PT1525177E (pt) 2007-09-06
JP4575771B2 (ja) 2010-11-04
NO329700B1 (no) 2010-12-06
US20070032543A1 (en) 2007-02-08
KR100974577B1 (ko) 2010-08-06
US20050176808A1 (en) 2005-08-11
CN100548960C (zh) 2009-10-14
CN1668565A (zh) 2005-09-14
JP2005532385A (ja) 2005-10-27
FR2841900B1 (fr) 2007-03-02
AU2003264698B2 (en) 2009-09-17
CA2490986C (fr) 2012-09-18
KR20050025327A (ko) 2005-03-14
DK1525177T3 (da) 2007-10-22
NZ538051A (en) 2007-11-30
MXPA05000427A (es) 2005-09-30
US7566737B2 (en) 2009-07-28
WO2004005233A1 (fr) 2004-01-15
IL165696A0 (en) 2006-01-15
ES2287528T3 (es) 2007-12-16
EA011090B1 (ru) 2008-12-30
ATE365703T1 (de) 2007-07-15
EP1525177B1 (fr) 2007-06-27
CY1108085T1 (el) 2014-02-12
CA2490986A1 (fr) 2004-01-15
US8058308B2 (en) 2011-11-15
IL165696A (en) 2012-09-24
PL207362B1 (pl) 2010-12-31

Similar Documents

Publication Publication Date Title
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
EA200501676A1 (ru) Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
EA200702109A1 (ru) Алкинилпирролопиримидины и их применение в качестве ингибиторов hsp90
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
EA200500299A1 (ru) Пиразольные композиции, используемые в качестве ингибиторов gsk-3
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
EA200201214A1 (ru) Замещенные тиоацетамиды
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
EA200400006A1 (ru) Бензоилсульфонамиды и сульфонилбензамидины для применения в качестве противоопухолевых агентов
EA200500392A1 (ru) Производные пиримидина и их применение в качестве модуляторов св2
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): MD RU